148 related articles for article (PubMed ID: 29985349)
1. Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells.
Zhou R; Xu A; Tu J; Liu M; Gingold JA; Zhao R; Lee DF
J Vis Exp; 2018 Jun; (136):. PubMed ID: 29985349
[TBL] [Abstract][Full Text] [Related]
2. Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.
Lin YH; Jewell BE; Gingold J; Lu L; Zhao R; Wang LL; Lee DF
Trends Mol Med; 2017 Aug; 23(8):737-755. PubMed ID: 28735817
[TBL] [Abstract][Full Text] [Related]
3. Modeling familial cancer with induced pluripotent stem cells.
Lee DF; Su J; Kim HS; Chang B; Papatsenko D; Zhao R; Yuan Y; Gingold J; Xia W; Darr H; Mirzayans R; Hung MC; Schaniel C; Lemischka IR
Cell; 2015 Apr; 161(2):240-54. PubMed ID: 25860607
[TBL] [Abstract][Full Text] [Related]
4. Modeling of osteosarcoma with induced pluripotent stem cells.
Pang LK; Pena M; Zhao R; Lee DF
Stem Cell Res; 2020 Dec; 49():102006. PubMed ID: 33022533
[TBL] [Abstract][Full Text] [Related]
5. Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.
Zhou R; Xu A; Gingold J; Strong LC; Zhao R; Lee DF
Trends Pharmacol Sci; 2017 Oct; 38(10):908-927. PubMed ID: 28818333
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism.
Kim H; Yoo S; Zhou R; Xu A; Bernitz JM; Yuan Y; Gomes AM; Daniel MG; Su J; Demicco EG; Zhu J; Moore KA; Lee DF; Lemischka IR; Schaniel C
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):E11128-E11137. PubMed ID: 30385632
[TBL] [Abstract][Full Text] [Related]
7. TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.
Ribi S; Baumhoer D; Lee K; Edison ; Teo AS; Madan B; Zhang K; Kohlmann WK; Yao F; Lee WH; Hoi Q; Cai S; Woo XY; Tan P; Jundt G; Smida J; Nathrath M; Sung WK; Schiffman JD; Virshup DM; Hillmer AM
Oncotarget; 2015 Apr; 6(10):7727-40. PubMed ID: 25762628
[TBL] [Abstract][Full Text] [Related]
8. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
9. Li-Fraumeni syndrome in pediatric patients with soft tissue sarcoma or osteosarcoma.
Carnevale A; Lieberman E; Cárdenas R
Arch Med Res; 1997; 28(3):383-6. PubMed ID: 9291635
[TBL] [Abstract][Full Text] [Related]
10. LncRNA H19 Suppresses Osteosarcomagenesis by Regulating snoRNAs and DNA Repair Protein Complexes.
Xu A; Huang MF; Zhu D; Gingold JA; Bazer DA; Chang B; Wang D; Lai CC; Lemischka IR; Zhao R; Lee DF
Front Genet; 2020; 11():611823. PubMed ID: 33519915
[TBL] [Abstract][Full Text] [Related]
11. Li-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer: increased expression of a CD44 variant isoform after chemotherapy.
Yoshida GJ; Fuchimoto Y; Osumi T; Shimada H; Hosaka S; Morioka H; Mukai M; Masugi Y; Sakamoto M; Kuroda T
BMC Cancer; 2012 Oct; 12():444. PubMed ID: 23031740
[TBL] [Abstract][Full Text] [Related]
12. Li-Fraumeni syndrome: a case report.
Ilić MP; Kiralj A; Markov B; Mijatov I; Mijatov S; Vučković N
Vojnosanit Pregl; 2014 Dec; 71(12):1159-62. PubMed ID: 25639008
[TBL] [Abstract][Full Text] [Related]
13. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition.
Valdez JM; Nichols KE; Kesserwan C
Br J Haematol; 2017 Feb; 176(4):539-552. PubMed ID: 27984644
[TBL] [Abstract][Full Text] [Related]
14. Differentiation of Mesenchymal Stem Cells from Human Induced Pluripotent Stem Cells Results in Downregulation of c-Myc and DNA Replication Pathways with Immunomodulation Toward CD4 and CD8 Cells.
Wang LT; Jiang SS; Ting CH; Hsu PJ; Chang CC; Sytwu HK; Liu KJ; Yen BL
Stem Cells; 2018 Jun; 36(6):903-914. PubMed ID: 29396902
[TBL] [Abstract][Full Text] [Related]
15. Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome.
Buzby JS; Williams SA; Schaffer L; Head SR; Nugent DJ
Cancer Genet; 2017 Feb; 211():9-17. PubMed ID: 28279309
[TBL] [Abstract][Full Text] [Related]
16. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
17. Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatrician.
Giacomazzi CR; Giacomazzi J; Netto CB; Santos-Silva P; Selistre SG; Maia AL; Oliveira VZ; Camey SA; Goldim JR; Ashton-Prolla P
Rev Assoc Med Bras (1992); 2015; 61(3):282-9. PubMed ID: 26248253
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic antibody directed osteogenic differentiation of induced pluripotent stem cell derived MSCs.
Wu Q; Yang B; Cao C; Hu K; Wang P; Man Y
Acta Biomater; 2018 Jul; 74():222-235. PubMed ID: 29778895
[TBL] [Abstract][Full Text] [Related]
19. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome.
Sugawara W; Arai Y; Kasai F; Fujiwara Y; Haruta M; Hosaka R; Nishida K; Kurosumi M; Kobayashi Y; Akagi K; Kaneko Y
Genes Chromosomes Cancer; 2011 Jul; 50(7):535-45. PubMed ID: 21484931
[TBL] [Abstract][Full Text] [Related]
20. A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma.
Reed MR; Lyle AG; De Loose A; Maddukuri L; Learned K; Beale HC; Kephart ET; Cheney A; van den Bout A; Lee MP; Hundley KN; Smith AM; DesRochers TM; Vibat CRT; Gokden M; Salama S; Wardell CP; Eoff RL; Vaske OM; Rodriguez A
Cells; 2021 Dec; 10(12):. PubMed ID: 34943910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
